Completed NA INTERVENTIONAL 1-arm NCT01910909

Stereotactic Body Radiotherapy for Unresectable Hepatocellular Carcinoma (SBRT for HCC)

Effectiveness and Safety of the Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Prospective Phase II Trial

Sponsor: Samsung Medical Center

Conditions Localized Non-Resectable Adult Hepatocellular Carcinoma

Interventions Stereotactic body radiotherapy

Updated 9 times since 2017 Last updated: Nov 20, 2023 Started: Aug 31, 2013 Primary completion: Apr 30, 2019 Completion: Apr 30, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01910909, this NA trial focuses on Localized Non-Resectable Adult Hepatocellular Carcinoma and remains completed. Sponsored by Samsung Medical Center, it has been updated 9 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Dec 2023 — Jul 2024 [monthly]

Completed NA

Status: Unknown Status → Completed
Jan 2021 — Dec 2023 [monthly]

Unknown Status NA

▶ Show 4 earlier versions

May 2020 — Jan 2021 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status
Jun 2018 — May 2020 [monthly]

Recruiting NA
May 2018 — Jun 2018 [monthly]

Recruiting NA

Phase: PHASE2 → NA
Jan 2017 — May 2018 [monthly]

Recruiting PHASE2

First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Samsung Medical Center

Data source: Samsung Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea